The Securities and Exchange Commission has announced that it has resolved civil FCPA charges against the French drug company, Sanofi, and its Kazakh and Middle Eastern subsidiaries. The company will pay $25 million to settle allegations that it participated in bribery schemes to secure government tenders and increase prescriptions.
September 4, 2018
Pharmaceutical giant charged with bribery
Related by Topic
New Post
Texas businessman pleads guilty to FCPA violations involving a Mexican official
April 2, 2026
News Alert
New Post
Mining company notifies SEC and DOJ of possible FCPA violations by an Indonesian affiliate
March 30, 2026
News Alert